Ports

Pharma Supply Chains Shift to Multi-Regional Model

The global pharmaceutical industry is moving toward geographically distributed production and innovation networks, with China, India, and the Middle East emerging as critical hubs alongside traditional Western centers.

China has evolved beyond a source of raw ingredients and manufacturing capacity to become a significant biotechnology and clinical development hub, according to Frank van Gelder, secretary general of Pharma.Aero. India continues to dominate generics production while expanding its innovative capabilities.

This fragmentation creates a "multi-polar pharmaceutical world" that requires logistics providers to adapt to interconnected, multi-node supply chains. The industry is shifting away from reliance on dominant origins and gateways toward networks linking multiple manufacturing sites, clinical centers, specialized logistics hubs, and healthcare delivery points.

The structural change presents new opportunities for airfreight and specialized logistics operators positioned to manage complex, distributed networks.